RxDoctor Payments Data

Florencia Perez, MD

Family Medicine · McAllen, TXNPI 1689715500

Payments from drug & device makers

$1,663in general payments, 2019–2025

Across 92 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$512
  • Novo Nordisk$268
  • Abbott$230
  • Pfizer$114
  • Cumberland Pharmaceuticals, Inc.$103
  • AbbVie$86
  • plus $349 from 11 others

What the payments were for

  • Food & beverage$1,663100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,663 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$64,860
Medicare patients
76
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$122,939
MounjaroTirzepatide65$72,833
FarxigaDapagliflozin Propanediol48$55,024
TrulicityDulaglutide38$53,994
JardianceEmpagliflozin42$49,340
XareltoRivaroxaban16$26,748
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,528
Tresiba Flextouch U-100Insulin Degludec23$15,155
NamzaricMemantine Hcl/Donepezil Hcl13$13,138
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$10,286
Lantus SolostarInsulin Glargine,hum.Rec.Anlog61$6,397
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen173$4,619
VascepaIcosapent Ethyl19$4,336
Albuterol Sulfate HfaAlbuterol Sulfate127$4,157
Levemir FlexpenInsulin Detemir16$3,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$512$126,827103 claims
Novo NordiskOzempic$268$122,93995 claims
AstraZenecaFarxiga$59$55,02448 claims
GSKTrelegy Ellipta$25$18,52823 claims
AbbVieNamzaric, Synthroid$86$14,61034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →